The future potential treatment of high-risk, progressive, nmHSPC

One of the clinical questions that is now beginning to be asked really seriously is this one: “Just how aggressively should we treat a man with high-risk progressive prostate cancer after first-line therapy?” … READ MORE …

Should you be adding abiraterone acetate to your ADT?

The data previously reported from the STAMPEDE trial and the LATITUDE trial over the past couple of days were from men newly diagnosed with high-risk and/or metastatic forms of prostate cancer, but … READ MORE …

ADT + radiation therapy in men with high-risk prostate cancer

So one of the more important papers that will be presented at the ASCO meeting in Chicago today will give us the 10-year results of the Canadian PCS IV trial. … READ MORE …

High-risk patients get conflicting messages from radiation oncologists and urologists after first-line surgical treatment

In spite of data suggesting that brachy boost has better outcomes for high-risk patients, it is being utilized less often and surgery is being utilized more often. … READ MORE …

For very high-risk patients, EBRT + BT is superior to surgery or EBRT only (redux)

In August last year, Kishan et al. showed a preliminary analysis of oncological outcomes among patients diagnosed with Gleason score 9 and 10 and treated with brachy boost therapy (EBRT + BT), external beam radiation therapy alone (EBRT), or surgery (see this link). … READ MORE …

Nadir PSA predicts survival after radiation and androgen deprivation for unfavorable risk patients

The following commentary addresses the article on risk for recurrent prostate cancer that we had mentioned briefly yesterday.

If a treatment isn’t working, we want to know as quickly as possible so we can try a salvage therapy while it can still make a difference. … READ MORE …

Early chemotherapy in treatment of high-risk and aggressive prostate cancers?

So the results from the CHAARTED and STAMPEDE trials over the past few years have re-ignited debate over the appropriateness of early use of chemotherapy in the treatment of aggressive forms of prostate cancer. … READ MORE …